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Aims Neutrophil gelatinase-associated lipocalin (NGAL) is a measure of acute kidney injury. Renal dysfunction portends
signiﬁcant risk after discharge from acute heart failure (AHF). Thus, a sensitive marker of renal injury might also
help to risk stratify HF patients.
Methods
and results
GALLANT [NGALEvaLuation AlongwithB-type NaTriureticPeptide (BNP)inacutelyDecompensatedHeart Failure]
was a multicentre, prospective study to assess the utility of plasma NGAL, alone and in combination with BNP, as an
early risk marker of adverse outcomes. We studied 186 patients (61% male). There were 29 events (AHF readmissions
and all-cause mortality) at 30 days (16%). Patients with events had higher levels of NGAL than those without (134 vs.
84 ng/mL, P , 0.001). The area under the receiver operating characteristic curve was higher for NGAL (0.72) than
BNP (0.65), serum creatinine (0.57), or estimated glomerular ﬁltration rate (eGFR; 0.55). In multivariable analyses,
NGAL predicted events (P ¼ 0.001), BNP approached signiﬁcance (P ¼ 0.052 and 0.070 without creatinine and
GFR, respectively) while neither serum creatinine nor eGFR were signiﬁcant. The addition of discharge NGAL over
BNP alone improved classiﬁcation by a net 10.3% in those with events and 19.5% in those without events, for a net
reclassiﬁcation improvement of 29.8% (P ¼ 0.010). Subjects with both BNP and NGAL elevated were at signiﬁcant
risk [hazard ratio (HR) ¼ 16.85, P ¼ 0.006], as were subjects with low BNP and high NGAL (HR ¼ 9.95, P ¼ 0.036).
Conclusions Plasma NGAL is a measure of kidney injury that at the time of discharge is a strong prognostic indicator of 30 days
outcomes in patients admitted for AHF.
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Renal dysfunction is common in patients with acute heart failure
(AHF) and is associated with signiﬁcant early and late morbidity
and mortality.
1,2 The fact that creatinine rise is a marker of renal
function and not renal injury makes it less sensitive to early
injury that might occur secondary to diuretic treatment, or other
causes of decreased renal perfusion, including elevated central
venous pressure.
3 This and the fact that it can take up to 2 days
for creatinine to increase after an ‘insult’ to the renal tubules
make it less appealing than a potential speciﬁc early rising
marker of renal injury and, therefore, as a risk predictor in these
patients.
3,4
Neutrophil gelatinase-associated lipocalin (NGAL) is a member
of the lipocalin family of proteins. Neutrophil gelatinase-associated
lipocalin is produced in the kidney following ischaemic or nephro-
toxic injury in both animals and humans.
5–11 Dent et al.
12 demon-
strated that NGAL was effective in identifying acute kidney injury
(AKI) 2–3 h after cardiopulmonary bypass surgery as compared
with 2–3 days for creatinine. In chronic HF urinary NGAL levels
are elevated,
1 while Damman et al. demonstrated that admission
serum NGAL levels were associated with heightened risk of sub-
sequent development of worsening renal function (WRF) in
patients admitted for AHF.
1,3
B-type natriuretic peptide (BNP) is a well-established marker for
the diagnosis of AHF.
13–15 Importantly, it has been clearly demon-
strated that BNP levels at discharge are highly predictive of short-
term outcomes.
16 Ideally if BNP, which is a marker for ventricular
stretch and a surrogate for pulmonary congestion,
17 could be
matched with a marker of renal injury, the combination would
be quite useful for risk stratiﬁcation.
The GALLANT trial was a multicentre prospective pilot clinical
study to assess the utility plasma NGAL—alone and in conjunction
with the BNP—as an aid to early risk assessment for HF-related
adverse clinical outcomes (deaths, readmissions, and additional




We studied patients who were .18 years of age, and who presented
to the emergency department (ED) or hospital with symptoms of new
or decompensated HF in whom diuretics were an expected part of
therapy. B-type natriuretic peptide levels were required to be
≥100 pg/mL and patients were also required to have systolic or dias-
tolic dysfunction as documented on an echocardiogram within the past
12 months or during hospitalization. Patients were excluded if there
was evidence of acute myocardial infarction or active ischaemia, car-
diogenic shock, or any other clinical condition that might preclude
administration of diuretics. Patients were also excluded if they had
renal failure (serum creatinine ≥3.0, on dialysis (either acute or
chronic) or in imminent need of dialysis). Patients who had received
intravenous diuretic treatment for .90 min prior to enrolment
were also excluded. Finally, patients with known or suspected infection
with human immunodeﬁciency virus (HIV) or infectious hepatitis were
excluded.
Ethylenediaminetetraacetic acid (EDTA) anticoagulated whole blood
was collected for the NGAL and BNP measurements. Specimens were
centrifuged (10 min at 2000 g) within 1 h of collection and the plasma
was frozen at ,708C prior to analysis. Creatinine was measured on
serum specimens.
Once written informed consent had been obtained, baseline demo-
graphic data were recorded and blood samples were obtained for
measurements of creatinine, NGAL, and BNP. These were repeated
daily for up to 5 days as well as at discharge. Discharge samples
were used for the analysis of the prognostic value of NGAL and
BNP for adverse HF-related outcomes. Patients were followed for
30 days following discharge for HF readmission or all-cause mortality.
The combined endpoint was considered to have been met if the
patient experienced AHF readmission or all-cause mortality during
the follow-up period. The institutional review boards of the enrolling
institutions approved this study. The ﬁve participating study centres
and corresponding patient numbers are given in Table 1.
Measurements
The Triage NGAL Test (Alere Inc, San Diego, CA, USA) is an immu-
noassay in a single-use plastic cartridge that contains a ﬂuorescently
labelled monoclonal antibody against NGAL labelled with a ﬂuorescent
dye and NGAL. There are built-in control features, including control
immunoassays, to ensure that the test performs properly and the
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Mean SD Mean SD
Age (years) 68.2 15.3 70.8 14.1 0.381
BMI 28.5 8.8 30.9 8.9 0.171
BP systolic (mmHg) 123.1 30.7 142.8 30.0 0.001
BP diastolic (mmHg) 72.2 12.8 81.8 17.7 0.006






n % n %
Male 19 65.5 96 60.4 0.682
White race 17 58.6 101 63.5 0.678
Black race 7 24.1 39 24.5 1.000
Orthopnoea 16 55.2 90 56.6 1.000
PND 10 34.5 44 27.7 0.505
Dyspnoea on exertion 22 75.9 121 76.1 1.000
Dyspnoea at rest 10 34.5 51 32.1 0.831
Rales 5 17.2 28 17.6 1.000
Wheezing 5 17.2 30 18.9 1.000
S3 1 3.4 4 2.5 0.572
S4 0 0.0 1 0.6 1.000
JVP 9 31.0 34 21.4 0.335
Peripheral oedema 21 72.4 120 75.5 0.816
EF , 45% 11/20 55.0 39/77 50.6 0.729
Note: Study centres and patient numbers were as follows: San Diego VA Hospital
(n ¼ 41), Ohio State University (n ¼ 11), New York Methodist Hospital (n ¼ 91),
University Medical Center, Groningen (n ¼ 23), and Universita ¨tsspital, Basel (n ¼ 22).
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addition of several drops of whole blood or plasma to the sample
port on the test device. After addition of the sample, the cells are auto-
matically separated from the plasma via a ﬁlter. The sample reacts with
ﬂuorescent antibody conjugates within the reaction chamber and ﬂows
down the device detection lane by capillary action. The ﬂuorescent
antibody conjugates are captured on discrete solid-phase zones result-
ing in binding immunoassays that are speciﬁc for NGAL or the control
antigens. B-type natriuretic peptide testing was also performed on the
Triage platform using a standard commercially available assay (Triage
Assay, Alere Inc.). Estimated glomerular ﬁltration rate (eGFR) was cal-
culated as MDRD as per Smilde et al.
16
Statistical analysis
Continuous variables are expressed as mean (standard deviation) and
compared using t-tests for independent groups if normally distributed;
otherwise, they are expressed as medians [quartiles] and compared
with Mann–Whitney U tests. Receiver operating characteristic
(ROC) analysis was performed to evaluate individual marker prognos-
tic utility for the combined endpoint and to ascertain cut-points yield-
ing 80% sensitivity. The areas under the ROC curves (C-statistics)
were compared using the method of DeLong et al.
17 Relationships
between biomarkers were evaluated with Spearman rank-order corre-
lation. Kaplan–Meier methods were employed to generate survival
plots that were compared using a log-rank test. Cox proportional
hazards regression was employed to evaluate survival models using
biomarkers with common log transformations for NGAL and BNP
to achieve normality, and using biomarker cut-points. Net reclassiﬁca-
tion improvement
20 was calculated based on risk levels of 6 and 20% as
cut-points. A signiﬁcance criterion of 0.05 without correction for mul-
tiple comparisons was employed throughout.
Results
There were 194 patients who met the inclusion criteria, of whom
six were excluded due to loss to follow-up (n ¼ 3) or withdrawal
(n ¼ 1), or HF not being the ﬁnal diagnosis (n ¼ 2). Twenty-nine
subjects reached an endpoint of all-cause mortality or HF readmis-
sion by 30 days (16%). Table 1 shows the demographics of patients
with or without events. The overall sample was 61% male with a
mean age of 71+13.8 years. Subjects with events were not differ-
ent from subjects without events with respect to age, gender,
symptoms, and physical ﬁndings. Only systolic and diastolic blood
pressures were signiﬁcantly different between groups.
Figure 1 depicts discharge levels of NGAL, BNP, serum creati-
nine, and eGFR in those with and without 30 days events. Those
with events had higher levels of NGAL than those without
events (134 ng/mL [104–181] vs. 84 ng/mL [59–128], P ,
0.001). Patients with events also had higher discharge BNP levels
(585 pg/mL [375–1380]) than those without (384 pg/mL [172–
818] P ¼ 0.013). Neither discharge creatinine nor eGFR were sig-
niﬁcantly different between patients with and without events. At
baseline, NGAL levels were already different for those with
events than those without (112 ng/mL [75–153] vs. 72 ng/mL
[60–120], P ¼ 0.006) while BNP levels did not differ (837 pg/mL
[500–1465] vs. 672 pg/mL [359–1350], P ¼ 0.180).
Figure 2 shows the area under the ROC curve for NGAL, BNP,
creatinine, and eGFR for predicting 30 days HF-related adverse
events. The area under the ROC curve (or C-statistic) was
higher for NGAL (0.73) than for BNP (0.65), serum creatinine
(0.57), or eGFR (0.55). Comparing C-statistics, NGAL was
superior to creatinine (P ¼ 0.004) and eGFR (P ¼ 0.002), but not
to BNP (P ¼ 0.21). B-type natriuretic peptide, however, was not
Figure 1 Box plots of markers at discharge. Boxes indicate medians and quartiles, whiskers indicate 10th and 90th percentiles.
A.S. Maisel et al. 848signiﬁcantly different to creatinine (P ¼ 0.33) or eGFR (P ¼ 0.24).
Discharge eGFR and creatinine were also not signiﬁcantly different
(P ¼ 0.50).
The correlation of NGAL levels was modest with creatinine
(r ¼ 0.42, P , 0.001) and eGFR (r ¼ 0.44, P , 0.001) and weak
with BNP (r ¼ 0.22, P ¼ 0.002). Multiple linear regression was
used to predict NGAL levels from these variables.
Table 2 shows Cox regression models with either eGFR or crea-
tinine in the model. In these multivariable analyses, neither log
serum creatinine nor eGFR were signiﬁcant for 30 days events,
but log NGAL (P , 0.001 for both models) was a signiﬁcant pre-
dictor of events and the log BNP values approached signiﬁcance
(P ¼ 0.052 and 0.070). Using risk cut-points of 6 and 20%, subjects
were divided into 30 days risk groups using log BNP alone or log
BNP and log NGAL. The addition of NGAL to the model
improved classiﬁcation by a net 10.3% in those with events and
19.5% in those without events, for a net reclassiﬁcation improve-
ment of 29.8% (P ¼ 0.010).
Using cut-points at the level of 80% sensitivity for BNP (330
pg/mL) and NGAL (100 ng/mL), subjects were sorted by high/
low BNP and high/low NGAL. Table 3 shows a Cox regression
model with the four groups. As can be seen, when NGAL is
low, a high BNP delineates no signiﬁcant risk. However, when
BNP is low, a high NGAL still portends signiﬁcant risk. When
both markers were elevated the risk was substantial (HR ¼ 16.9,
95% CI ¼ 2.3–195.9, P ¼ 0.006). Figure 3 depicts Kaplan–Meier
curves for these four groups. As shown, high-BNP/high-NGAL
had the worst outcomes and survival rate was high when both
markers were low. While the risk in the low-BNP/high-NGAL
group was signiﬁcant, the high-BNP/low-NGAL group had out-
comes similar to when both markers were low.
Discussion
The main ﬁnding of the present study is that plasma NGAL at the
time of hospital discharge is a powerful predictor of 30 days
outcome in patients with AHF. It is stronger than BNP, which is
considered to be the standard for risk prediction, and is substan-
tially superior to conventional measures of renal function such as
serum creatinine and eGFR. Thus, NGAL is not only a risk predic-
tor for renal injury but is an overall strong risk marker for cardiac
events in the setting of HF.
Physicians now recognize that HF entails a disorder at the level
of both the heart and the kidneys. Worsening renal function is
especially common during admission for acute decompensated
HF and is associated with a poor prognosis.
19–31 While the under-
lying causes of WRF are multifactorial, the combination of
angiotensin-converting enzyme-inhibitors and intravenous diuretics
likely are large contributors. The shortcomings of creatinine as a
predictor of acute renal dysfunction are well known. Serum crea-
tinine lacks the sensitivity to detect changes in GFR, as its increase
is delayed by the need for accumulation once there is a reduction
in GFR. Even if not present at the time of admission, kidney injury
can ensue during diuresis at the tail end of the hospital period, and
may not be manifest (in terms of elevated serum creatinine) at the
time of discharge. While serum creatinine and eGFR are clearly
.......................
................................................................................
Table 2 Multivariable Cox models for risk of heart
failure re-hospitalization or all-cause mortality
Biomarker P HR 95% CI for HR
Lower Upper
Model with eGFR
lg BNP (pg/mL) 0.052 2.47 0.99 6.14
lg NGAL (ng/mL) 0.000 29.83 5.43 163.96
eGFR (mL/min/1.73 m
2) 0.284 1.01 0.99 1.02
Model with creatinine
lg BNP (pg/mL) 0.070 2.327 0.934 5.795
lg NGAL (ng/mL) 0.001 19.912 3.472 114.189
lg creatinine (mg/dL) 0.891 1.177 0.115 12.064
Figure 2 Receiver operating characteristic curve analysis for




Table 3 Cox models for risk of heart failure
re-hospitalization or all-cause mortality in groups based
on neutrophil gelatinase-associated lipocalin and B-type
natriuretic peptide cut-offs
Group P HR 95.0% CI for HR
Lower Upper
NGAL , 100, BNP , 330 0.002 1.00 reference
NGAL , 100, BNP . 330 0.294 3.23 0.36 28.93
NGAL . 100, BNP , 330 0.036 9.95 1.16 85.19
NGAL . 100, BNP . 330 0.006 16.85 2.26 125.94
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injury that rises early should reﬂect the state of tubular function
at the time of discharge.
Neutrophil gelatinase-associated lipocalin is one of the earliest
markers produced in the kidney following ischaemic or nephro-
toxic injury in animal models, and it can be detected in the
blood and urine of humans soon after AKI
6–12 Several studies
have conﬁrmed these ﬁndings. In intensive care adult patients
with AKI secondary to sepsis, ischaemia, or nephrotoxins, NGAL
is signiﬁcantly increased in the plasma and urine when compared
with normal controls.
12 In children undergoing cardiopulmonary
bypass, NGAL was increased signiﬁcantly in plasma and urine
2–6 h after surgery in those patients who subsequently developed
AKI; the rise in creatinine was not evident until 48–72 h later. In
this setting, both urine and plasma NGAL were powerful indepen-
dent predictors of AKI, with an outstanding area under the curve
of 0.998 for 2 h urine NGAL levels and 0.91 for 2 h plasma
NGAL measurement. Similar ﬁndings have been reported in
adults who develop AKI after cardiac surgery, with NGAL
elevation occurring 1–3 h after surgery.
6
Neutrophil gelatinase-associated lipocalin
and B-type natriuretic peptide:
implications for risk stratiﬁcation
Assessment of blood BNP levels is now commonly performed in
the ED to aid in the diagnosis of AHF in patients presenting with
acute dyspnoea. The clinical utility of assessing BNP levels in the
ED has been conﬁrmed and described in detail in the scientiﬁc
literature.
13–16,30 B-type natriuretic peptide concentrations
measured during hospital admission and/or at discharge in patients
with HF have also been shown to provide prognostic information
about the patient’s subsequent risk of death or
rehospitalization.
16,17
While BNP is a marker of ventricular stretch, and therefore a
surrogate of volume overload, NGAL is a marker of renal
tubular injury that is both diagnostic and prognostic. Haase
et al.
31 recently presented a meta-analysis consisting of 1217
patients, with clinical outcomes of AKI patients according to
NGAL and creatinine status. A major ﬁnding was that 41% of
patients diagnosed with AKI would have been missed by creatinine
alone. Neutrophil gelatinase-associated lipocalin tended to identify
increased risk even when the creatinine was not signiﬁcantly
changed. Damman et al.
1 demonstrated that structural tubular
damage, as measured by increased concentrations of NGAL, is
highly prevalent in patients with chronic HF. While the Damman
study differed from ours in that urinary NGAL was not prognostic,
the acute nature of our patients and the use of blood rather than
urine, may have accounted for the difference in prognostic effect
observed. Thus, across the spectrum of HF and healthy controls,
NGAL levels are not only associated with different indices of
renal dysfunction, but also positively associated with increased
levels of natriuretic peptides.
In our study, subjects with the combination of high BNP/high
NGAL had the worst outcomes; survival rate was high when
both markers were low. While the risk in the low BNP/high
NGAL group was signiﬁcant, the high BNP/low NGAL group had
outcomes similar to when both markers were low. This may be
due to the fact that even though the BNP was high, it likely rep-
resented, ‘dry’ not ‘wet’ BNP. Thus, at the time of discharge,
two easy to measure biomarkers: one of ventricular stretch (and
volume overload) and one of renal tubular injury offer powerful
risk stratiﬁcation. Perhaps treatments to effectively lower BNP
levels to euvolaemic ‘dry’ states without leading to decreases in
renal perfusion, subsequent tubular ischaemia, and rising NGAL
Figure 3 Kaplan–Meier plots of heart failure re-hospitalization free survival based on cut-offs of 100 ng/mL for neutrophil
gelatinase-associated lipocalin and 330 pg/mL for B-type natriuretic peptide. Log rank test P , 0.001.
A.S. Maisel et al. 850levels might offer the patient a better chance of improved survival
and improved quality of life once they are discharged from the hos-
pital. One might speculate that a high NGAL at the time of dis-
charge might at a minimum, be a signal for early and perhaps
more frequent follow-up and a judicious use of outpatient
diuretics.
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